Stockholm, February 27, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:

  • TD Cowen 44th Annual Health Care Conference

Location: Boston, MA.
Presenter: Ahmed Mousa, CEO
Presentation Date and Time: March 6 at 12:50 PM ET/6:50 PM CET
Webcast Registration: Link

  • Carnegie Nordic Healthcare Seminar

Location: Stockholm, Sweden
Presenter: Mikael Nygård, VP Operations and Corporate Strategy
Presentation Date and Time: March 6 at 9:00 AM ET/3:00 PM CET

For further information, please contact:
Ahmed Mousa, CEO, tel: +1 607 437 0235, ahmed.mousa@vicorepharma.com  
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

This information was submitted for publication on February 27, 2024, at 08:00 CET.

About Vicore Pharma Holding AB (publ)
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see  www.vicorepharma.com.

Attachments
Vicore to Present at Upcoming Investor Conferences

© Modular Finance, source Nordic Press Releases